Opinion/decision on a Paediatric investigation plan (PIP): Autologous CD34+enriched cells from patients with Fanconi anaemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene (PGK-FANCA-WPRE), decision type: , therapeutic area: , PIP number: P/0114/2020

Opinion/decision on a Paediatric investigation plan (PIP): Etripamil, decision type: , therapeutic area: , PIP number: P/0349/2022

Opinion/decision on a Paediatric investigation plan (PIP): Eptinezumab, decision type: , therapeutic area: , PIP number: P/0341/2022

Medicinal products for human use: monthly figures - July 2023

Human medicines European public assessment report (EPAR): Rinvoq, upadacitinib, Arthritis, Rheumatoid, Date of authorisation: 16/12/2019, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Perjeta, pertuzumab, Breast Neoplasms, Date of authorisation: 04/03/2013, Revision: 22, Status: Authorised

Shortage of Abraxane (paclitaxel)

Human medicines European public assessment report (EPAR): Lupkynis, voclosporin, Lupus Nephritis, Date of authorisation: 15/09/2022, Revision: 2, Status: Authorised

Opinion/decision on a Paediatric investigation plan (PIP): zuranolone, decision type: , therapeutic area: , PIP number: P/0358/2022

Human medicines European public assessment report (EPAR): NovoMix, insulin aspart, Diabetes Mellitus, Date of authorisation: 01/08/2000, Revision: 29, Status: Authorised